View Older Stories View More Recent Stories
-
Roth CH Acquisition I Co. (ROCH) Prices 7.5M Unit IPO at $10/Unit
-
UPDATE: Roth Capital Downgrades Five9, Inc (FIVN) to Neutral
-
Roth CH Acquisition I Co. Announces Pricing of $75 Million Initial Public Offering
-
LeMaitre Vascular (LMAT) EPS Drops ~70% at Roth Capital
-
Delcath Systems (DCTH) IPO Opens at $12.75
-
Delcath Systems (DCTH) Prices 2.2M Share Common Offering at $10/Sh and Uplisting to Nasdaq Capital Market
-
Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
-
Roth Capital Starts Lumos Pharma (LUMO) at Buy
-
Roth Capital Downgrades Inovio Pharmaceuticals (INO) to Neutral on Valuation
-
UPDATE: Roth Capital Starts Celsius Holdings (CELH) at Buy
-
Companies with NDRs 4/29
-
Roth Capital Starts Workhorse Group (WKHS) at Buy
-
Roth Capital Assumes Blue Bird Corp (BLBD) at Neutral
-
Roth Capital Reinstates Diamondback Energy (FANG), Upgrades to Buy
-
Companies with NDRs 4/28
-
Roth Capital Transfers Coverage on Cyclacel Pharmaceuticals (CYCC) at Buy
-
Pretium Resources (PVG) PT Raised to $9.25 at Roth Capital
-
Cyclacel Announces Closing of $20 Million Public Offering
-
Cyclacel Announces Closing of $20 Million Public Offering
-
Roth Capital Upgrades Talos Energy (TALO) to Buy
-
Companies with NDRs 4/24
-
Immunic Inc. (IMUX) Announces $15M Registered Direct Offering of Common Stock
-
Immunic, Inc. Announces Pricing of $15 Million Financing
-
Pre-Open Stock Movers 04/22: (IMUX) (SNAP) (CMG) Higher; (VBIV) (IBKR) (BIIB) Lower (more...)
-
UPDATE: Roth Capital Starts Compugen (CGEN) at Buy
-
One Stop Systems Announces Debt Financing
-
One Stop Systems Announces Debt Financing
-
Cyclacel Pharma (CYCC) Prices $20M Offering of Common Stock, Warrants
-
CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
-
Roth Capital Upgrades Landec (LNDC) to Buy
-
CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
-
Roth Capital Downgrades Goodrich Petroleum (GDP) to Neutral
-
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Allied Motion Technologies (AMOT) PT Lowered to $44 at Roth Capital
-
Roth Capital Starts The Lovesac Co. (LOVE) at Buy
-
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
MoSys (MOSY) Announces Pricing of $1.9 Million Registered Direct Offering of Common Stock
-
MoSys Announces Pricing of $1.9 Million Financing
-
Roth Capital Upgrades W&T Offshore (WTI) to Buy
-
Arcturus Therapeutics (ARCT) Prices 4.12M Share Common Stock Offering at $17/sh
-
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock
-
Reed's (REED) Prices 13.3M Share Public Offering of Common Stock at $0.35/sh
-
Reed’s Inc. Prices Underwritten Public Offering of Common Stock
-
Reed's (REED) Plans Public Offering of Common Stock
-
Reed’s Inc. Announces Proposed Public Offering of Common Stock
-
Moderna (MRNA) PT Raised to $41 at Roth Capital
-
Roth Capital Resumes Lakeland Industries (LAKE) at Buy
-
Roth Capital Downgrades Yeti Holdings Inc. (YETi) to Neutral
-
Crinetics Pharmaceuticals (CRNX) Prices 7.15M Share Common Offering at $14/Sh

